We are live on ! Find out more
RLMD icon

Relmada Therapeutics

83 hedge funds and large institutions have $56.4M invested in Relmada Therapeutics in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 26 increasing their positions, 20 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 20

4.55% less ownership

Funds ownership: 49.8% → 45.25% (-4.6%)

5% less funds holding

Funds holding: 87 → 83 (-4)

13% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 16

36% less capital inflows, than outflows

Capital inflows: $7.3M | Capital outflows: $11.3M

79% less call options, than puts

Call options by funds: $296K | Put options by funds: $1.41M

Holders
83
Holders Change
-4
Holders Change %
-4.6%
% of All Funds
1.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
26
Reduced
20
Closed
16
Calls
$296​K
Puts
$1.41​M
Net Calls
-⁠$1.12​M
Net Calls Change
-⁠$342​K

RLMD Hedge Fund Activity: Q4 2023 in Review

83 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q4 2023, worth a combined $56.4M — up 25% from $45M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of RLMD and 14 opened new positions — a net loss of 2 holders — while 20 trimmed existing stakes and 26 added.

The largest buyer was Opaleye Management, adding an estimated $2.51M. The largest seller was RTW Investments, exiting entirely with an estimated $6.4M sold.

  • 83 institutional investors held Relmada Therapeutics (RLMD) as of Q4 2023, down from 87 in Q3 2023.
  • Funds reported $56.4M of Relmada Therapeutics stock for Q4 2023, up 25% quarter-over-quarter.
  • 14 funds opened new Relmada Therapeutics positions in Q4 2023 and 16 closed out, a net change of -2 holders.
  • The largest Relmada Therapeutics buyer in Q4 2023 was Opaleye Management, an estimated $2.51M added.
  • The largest Relmada Therapeutics seller in Q4 2023 was RTW Investments, an estimated $6.4M sold.

Based on aggregated 13F filings for Q4 2023.